Safety and Immune Response of a Rabies Vaccine With the Essen Schedule and a Two-Dose Booster

Inclusion Criteria: * Healthy subjects aged 10-60 years as established by medical history and clinical examination * The subjects are able to understand and sign the informed consent * Female subjects aged 18-60 years must have a negative urine pregnancy test result and commit to using contraception for 2 months following the first vaccine dose in this study. * Subjects who can and will comply with the requirements of the protocol * Subjects with temperature ≤37.0°C on axillary setting Exclusion Criteria: Exclusion Criteria for the first dose: * Subject who was administered human rabies vaccine or rabies immunoglobulin. * Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, especially allergic to neomycin. * Has been diagnosed or suspected of having an immune deficiency, autoimmune disease, or immune system disorder. * History of thyroidectomy, or thyroid disease requiring treatmentin the past 12 months * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with injections or blood draws * History of epilepsy, convulsions or convulsions, or a family history of psychosis. * Absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy. * Have a malignant tumor in active phase, or a tumor that have been treated but not clearly cured, or may relapse during the study period. * In the past 6 months, there have been immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis). * Taking anti-TB or HIV treatment. * Any prior administration of immunoglobulin or blood products in last 3 months. * Coagulopathy (such as coagulation factor deficiency, coagulative disorders, platelet abnormalities) or obvious bruising or coagulation impairment * Any prior administration of other research drugs in last 30 days * Any prior administration of attenuated live vaccine in last 4 weeks * Any prior administration of subunit or inactivated vaccines in last 2 weeks * Have acute diseases, severe chronic diseases, acute exacerbation of chronic diseases, or those with fever * Suspected or have a history of injury caused by warm-blooded mammals in last 3 months. * Women who are breastfeeding, pregnant, or planning to become pregnant in 2 months past the first dose. * Use of antipyretic, analgesic, or antiallergic drugs within 3 days * Having used other investigational or unregistered products (drugs or vaccines) within 6 months prior to the vaccination of the study vaccine, or having plans to participate in other clinical studies after enrollment in this clinical study (except for emergency-use novel coronavirus vaccines, but the vaccination details must be recorded in the concomitant medication section) * Planning to move out of the local area or be away from the local area for a long time before the end of the study; * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives Exclusion Criteria for other doses: * Any incidences in the first dose exclusion criteria occur after inclusion * Grade 3 or higher systemic adverse reactions related to this study, or intolerable injection site adverse reactions, that occurred between the previous vaccination and the current vaccination. * Any serious adverse events caused by vaccination. * Other reactions that in the opinion of the investigator ( include: severely serious symptom of pain, swelling, Limitation of motion, continuous high fever, headache and other Systemic or local reactions )